Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29170211 | 0.75 | — | — | |
| SCHEMBL28608920 | 0.73 | — | — | |
| SCHEMBL188295 | 0.72 | CA1 (0.37) | CA1CA2CA9 | |
| SCHEMBL2293102 | 0.71 | TSHR (0.39) | CA2 | |
| SCHEMBL29155108 | 0.71 | — | — | |
| SCHEMBL8821777 | 0.71 | — | — | |
| SCHEMBL7235027 | 0.71 | ALDH1A1 (0.48) | — | |
| SCHEMBL8884453 | 0.70 | CA1 (0.31) | CA1CA2CA9 | |
| Lithium Ion SCHEMBL28518085 | 0.69 | — | — | |
| Lithium Ion SCHEMBL8821830 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3608328-B1 | METHOD FOR PRODUCING PHOSPHORYL IMIDE SALT, METHOD FOR PRODUCING NONAQUEOUS ELECTROLYTE SOLUTION CONTAINING SAID SALT, AND METHOD FOR PRODUCING NONAQUEOUS SECONDARY BATTERY | CENTRAL GLASS CO LTD (JP) | 2023-04-26 | — | — | EP | disclosed |
| CN-110520431-B | Method for producing phosphoryl imide salt, method for producing nonaqueous electrolyte solution containing the same, and method for producing nonaqueous secondary battery | 中央硝子株式会社 | 2022-02-18 | — | — | CN | disclosed |
| US-11230564-B2 | Method for producing phosphoryl imide salt, method for producing nonaqueous electrolyte solution containing said salt, and method for producing nonaqueous secondary battery | CENTRAL GLASS CO., LTD. (JP) | 2022-01-25 | — | — | US | disclosed |
| US-20210054005-A1 | METHOD FOR PRODUCING PHOSPHORYL IMIDE SALT, METHOD FOR PRODUCING NONAQUEOUS ELECTROLYTE SOLUTION CONTAINING SAID SALT, AND METHOD FOR PRODUCING NONAQUEOUS SECONDARY BATTERY | CENTRAL GLASS CO., LTD. (JP) | 2021-02-25 | — | — | US | disclosed |
| US-10851124-B2 | Method for producing phosphoryl imide salt, method for producing nonaqueous electrolyte solution containing said salt, and method for producing nonaqueous secondary battery | CENTRAL GLASS CO., LTD. (JP) | 2020-12-01 | — | — | US | disclosed |
| US-20200115401-A1 | METHOD FOR PRODUCING PHOSPHORYL IMIDE SALT, METHOD FOR PRODUCING NONAQUEOUS ELECTROLYTE SOLUTION CONTAINING SAID SALT, AND METHOD FOR PRODUCING NONAQUEOUS SECONDARY BATTERY | CENTRAL GLASS CO., LTD. (JP) | 2020-04-16 | — | — | US | disclosed |
| EP-3608328-A1 | METHOD FOR PRODUCING PHOSPHORYL IMIDE SALT, METHOD FOR PRODUCING NONAQUEOUS ELECTROLYTE SOLUTION CONTAINING SAID SALT, AND METHOD FOR PRODUCING NONAQUEOUS SECONDARY BATTERY | Central Glass Co., Ltd. (JP) | 2020-02-12 | — | — | EP | disclosed |
| CN-110520431-A | The manufacturing method of the manufacturing method of phosphorimide salt, the manufacturing method of nonaqueous electrolytic solution comprising the salt and non-aqueous secondary batteries | CENTRAL GLASS CO LTD | 2019-11-29 | — | — | CN | disclosed |
| EP-1204669-A1 | TRICYCLIC MONOSACCHARIDE DERIVATIVES USEFUL IN TREATING ACUTE ISCHEMIA-INDUCED NEURODEGENERATION | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001007453-A1 | TRICYCLIC MONOSACCHARIDE DERIVATIVES USEFUL IN TREATING ACUTE ISCHEMIA-INDUCED NEURODEGENERATION | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230564-B2 | Method for producing phosphoryl imide salt, method for producing nonaqueous electrolyte solution containing said salt, and method for producing nonaqueous secondary battery | PPM1F, PHOSPHO1, IPMK | CA1 322/4885CA2 134/4885CA9 351/4885 |
| US-10851124-B2 | Method for producing phosphoryl imide salt, method for producing nonaqueous electrolyte solution containing said salt, and method for producing nonaqueous secondary battery | PPM1F, PHOSPHO1, IPMK | CA1 322/4885CA2 134/4885CA9 351/4885 |
| US-20210054005-A1 | METHOD FOR PRODUCING PHOSPHORYL IMIDE SALT, METHOD FOR PRODUCING NONAQUEOUS ELECTROLYTE SOLUTION CONTAINING SAID SALT, AND METHOD FOR PRODUCING NONAQUEOUS SECONDARY BATTERY | PPM1F, PHOSPHO1, IPMK | CA1 322/4885CA2 134/4885CA9 351/4885 |
| US-20200115401-A1 | METHOD FOR PRODUCING PHOSPHORYL IMIDE SALT, METHOD FOR PRODUCING NONAQUEOUS ELECTROLYTE SOLUTION CONTAINING SAID SALT, AND METHOD FOR PRODUCING NONAQUEOUS SECONDARY BATTERY | PPM1F, PHOSPHO1, IPMK | CA1 322/4885CA2 134/4885CA9 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.